drugset
drugset / Trial / NCT06167486

SG2918 For Advanced Malignant Tumors

NCT06167486 ↗

Phase 1 Active not recruiting 17 enrolled Hangzhou Sumgen Biotech Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 in subjects with Advanced Malignant Tumors who are refractory or resistant to standard therapy, or without available standard or curative therapy.

Timeline

Start
2023-12-26
Primary completion
2025-11-11
Completion
2026-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject SG2918 Unknown 0.1 mg/kg Intravenous
Subject SG2918 Unknown 0.5 mg/kg Intravenous
Subject SG2918 Unknown 1 mg/kg Intravenous
Subject SG2918 Unknown 1.5 mg/kg Intravenous
Subject SG2918 Unknown 2 mg/kg Intravenous
Subject SG2918 Unknown 2.5 mg/kg Intravenous
Subject SG2918 Unknown 3 mg/kg Intravenous

Indications

cancer